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Abstract
The type III secretion system (T3SS) is a complex macromolecular machinery employed by a number of Gram-negative
pathogens to inject effectors directly into the cytoplasm of eukaryotic cells. ExoU from the opportunistic pathogen
Pseudomonas aeruginosa is one of the most aggressive toxins injected by a T3SS, leading to rapid cell necrosis. Here we
report the crystal structure of ExoU in complex with its chaperone, SpcU. ExoU folds into membrane-binding, bridging, and
phospholipase domains. SpcU maintains the N-terminus of ExoU in an unfolded state, required for secretion. The
phospholipase domain carries an embedded catalytic site whose position within ExoU does not permit direct interaction
with the bilayer, which suggests that ExoU must undergo a conformational rearrangement in order to access lipids within
the target membrane. The bridging domain connects catalytic domain and membrane-binding domains, the latter of which
displays specificity to PI(4,5)P2. Both transfection experiments and infection of eukaryotic cells with ExoU-secreting bacteria
show that ExoU ubiquitination results in its co-localization with endosomal markers. This could reflect an attempt of the
infected cell to target ExoU for degradation in order to protect itself from its aggressive cytotoxic action.
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Introduction
Type III secretion systems (T3SS) are needle-like, membrane-
anchored, multi-component complexes that enable a number of
pathogenic bacteria to inject effectors from the cytosol directly into
the cytoplasm of eukaryotic cells [1–6]. T3SS are widespread
among Gram-negative bacteria, and although the structure of the
T3SS apparatus itself can display notable similarities amongst
different bacterial species [5,7], the nature of translocated effectors
are widely different. Many T3SS-translocated proteins have been
shown to modulate cellular functions, i.e. by mimicking protein
kinases, phosphatases, GTPase activating proteins, or ubiquitin
ligases, or by covalently modifying target proteins through
phosphorylation or acetylation. The consequences to the target
cell may range from modifications of the cytoskeleton to
membrane disruption and apoptosis [8], underlining the key
nature of T3SS for extreme pathogenesis in a number of systems.
Pseudomonas aeruginosa is a leading cause of nosocomial infections
and is a major threat to cystic fibrosis patients and others with
impaired immune defenses. It carries a T3SS whose upregulation
during acute phases of infection is directly related to poor patient
prognosis [9,10], and which translocates four effectors, namely
exoenzymes S, T, U, and Y [11–13]. ExoS and ExoT are
bifunctional molecules with GTPase-activating (GAP) and ADP-
ribosyltransferase activities essential for the inhibition of bacterial
internalization and epithelial cell migration [14–19]. ExoY is an
adenylate cyclase reported to play a role in actin cytoskeleton
disruption and cause cell rounding [20–22]. However, it is ExoU
which is the most detrimental toxin injected by the T3SS of P.
aeruginosa. ExoU is expressed by approximately 30% of clinical
strains, 90% of which cause acute illness [10,11]. It is encoded on
a pathogenicity island together with its cognate chaperone SpcU,
which is required for ExoU’s efficient secretion from the bacterial
cytoplasm [23,24]. ExoU is a 687-residue protein that, once
translocated through the T3SS, induces cytotoxic effects leading to
rapid necrotic cell death; exoU knockout P. aeruginosa strains display
greatly decreased virulence in mouse models of acute infection
[25,26]. In clinical settings, ExoU-expressing P. aeruginosa strains
lead to poor patient prognosis, since the toxin causes acute lung
epithelial injury and is linked to the development of septic shock
[10,18,27–30]. To date, the precise mechanism underlying ExoU’s
significant potency for cellular destruction has remained unclear.
Notably, ExoU has been shown to carry phospholipase activity
with broad substrate specificity which relies on an essential
catalytic dyad (Ser142/Asp344) [24,31–33], as is the case for other
phospholipases. Enzymes with PLA2 activity hydrolyze the sn-2
ester bond of phospholipids, and thus play a role in membrane
disruption, fatty acid release, and in many cases, signal
transduction [34–36]. Interestingly, expression of ExoU in yeast
causes rapid fragmentation of the vacuolar compartment,
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toxin [33]. It is of note that the C-terminus of ExoU is critical for
its in vitro phospholipase activity and cellular cytotoxicity [32,37–
40]. In addition, pre-incubation with cellular extracts has been
shown to be essential for detection of phospholipase activity in vitro
[33,41], indicating the requirement for host eukaryotic cofactors in
order for ExoU to exert its phospholipase activity on lipidic
substrates. Eukaryotic Cu/Zn superoxide dismutase (SOD1) and
other ubiquitinated proteins, as well as ubiquitin itself, have been
suggested as being potential activators of the toxin [42–44].
The extreme toxicity of ExoU has limited functional studies of
the wild type form, necessitating the employment of a catalytically-
inactive mutant in cellular assays [31–33]. Trafficking studies of
the ExoU-Ser142Ala mutant in eukaryotic cells have revealed
that, upon translocation through the T3SS, ExoU is initially
targeted to the plasma membrane (PM). The membrane
localization potential of ExoU resides in its C-terminal domain
(specifically, in residues 679–683). ExoU trafficking to the PM
enables its ubiquitination on Lys178 [39], but this modification has
only a modest effect on ExoU turnover and an ExoU-K178R-
expressing mutant strain displays cytotoxicity levels that are similar
to those of the wild-type. These observations attest to the complex
fate of ExoU in target cells, which implies the coordination
between membrane targeting, phospholipase activity, activation by
cofactors, and ubiquitination.
In order to understand the multi-faceted behavior of ExoU, we
solved its crystal structure, which was achieved in the presence of
its chaperone, SpcU. ExoU forms a 1:1 complex with SpcU, and
folds into three distinct domains, which fulfill catalytic, bridging,
and membrane-binding functions. The active site of ExoU is
localized within an a/b hydrolase fold in a cleft sheltered by
flexible loop regions, thus suggesting an inactive conformation that
would require a structural modification to allow access of the
nucleophilic serine to the lipidic substrates on the plasma
membrane. The localization of Lys178 in proximity to the active
site region implies that such structural rearrangements could also
facilitate ubiquitination of ExoU by PM-localized E3 ligases.
Ubiquitinated ExoU co-localizes with markers of endosomal
compartments both upon transfection of cultured cells and
infection of eukaryotic cells by an ExoU-expressing P. aeruginosa
strain. This reflects a potential attempt of the cell to eliminate the
toxin by targeting it for lysosomal destruction.
Results
SpcU’s type IA fold stabilizes the N-terminus of ExoU
The structure of the ExoU(30–687):SpcU(1–127) complex was
solved to a resolution of 2.94 A ˚ by performing a SAD experiment
on the selenium edge at the ESRF synchrotron in Grenoble
(Supplementary Table I), and harbors a 1:1 complex in the
asymmetric unit. This stoichiometry is unusual, since SpcU has a
typical type IA T3SS chaperone fold (Figure 1), and complexes
between T3SS effectors and type I chaperones typically associate
with stoichiometries of 1:2 [3,5,45]. In order to determine the
precise stoichiometry of ExoU:SpcU in vitro, we performed native
mass spectrometry measurements of the purified complex, which
allowed us to identify a mixture of two distinct stoichiometric
species, 1:1 and 1:2. Interestingly, close analysis of the structure
reveals how both stoichiometries are possible in the crystal lattice.
SpcU is a typical type IA chaperone, being composed of a
curved, 5-stranded sheet flanked by a-helices. SpcU displays two
hydrophobic patches that recognize the effector. One involves the
extremity of the 5-stranded b-sheet, which binds a short b-strand
located at the N-terminus of ExoU (residues 62–64), thus
generating a 6-stranded sheet (Figures 1c and S1). This binding
region corresponds to the b motif that is also present in SipA:InvB,
SptP:SicP, YopH:SycH, and YopE:SycE complexes [46–48]. An
additional hydrophobic region of SpcU, located at the center of
the b-sheet, binds a region of ExoU that is partly disordered in the
electron density map. It is conceivable that this region corresponds
to the flexible N-terminus of ExoU that is stabilized in a symmetry-
related SpcU molecule. This becomes more evident upon the
generation of an ExoU:SpcU dimer (Figure S1c) based on the
possible biological assemblies calculated by PISA (http://www.ebi.
ac.uk/msd-srv/prot_int/picite.html), as well as by symmetry
within the C2 cell, which suggests that the flexible N-terminus of
ExoU in fact wraps around the crystallographic SpcU dimer by
employing two different hydrophobic patches on the chaperone
(the ‘‘front’’ and the ‘‘back’’, Figures S1b, S1c). It is of interest that
the effectors in the abovementioned 1:2 complexes display N-
termini that surround their respective chaperone dimers in
comparable fashion. Thus, it is conceivable that in vitro, both
ExoU:SpcU stoichiometric forms exist in equilibrium, but the 1:1
form, presented here, is the one that crystallizes in the asymmetric
unit of a C2 cell. Notably, the complex between the Yersinia pestis
chaperone SycH and a fragment from the effector YscM2 also
crystallized with 1:1 stoichiometry, with the effector wrapped
around the chaperone in a similarly extended conformation [49].
This association presumably ensures that the N-terminus of
ExoU is ready for translocation through the T3SS, and is also in
agreement with data indicating that the minimal domain required
for cytotoxicity begins in a region residing between residues 52 and
100 [50]; in fact, the last residue in the N-terminal region of ExoU
that makes contacts with SpcU is Ser65.
ExoU folds into three independent domains
Immediately following the SpcU-bound N-terminus of ExoU is
the first part of the bridging domain, which precedes the catalytic
region. The bridging domain of ExoU consists of two subdomains:
an N-terminal 4-stranded region (cyan and yellow in Fig. 1b) and
an all-helical section (yellow in Figures 1b and S2). Notably, the
ExoU sequence that immediately follows the N-terminal, SpcU-
associated region contributes 3 b-strands to the 4-stranded sheet of
the first subdomain (b2–b4). The catalytic domain is intercalated
Author Summary
Pseudomonas aeruginosa is a leading cause of nosocomial
infections and is a particular threat for cystic fibrosis and
immunodepressed patients. One of the most aggressive
toxins in its arsenal is ExoU, injected directly into target
cells by a needle-like complex located on the surface of the
bacterium, the type III secretion system. P. aeruginosa
strains that express ExoU cause rapid cell death as a
consequence of the membrane-destruction (phospholi-
pase) potential of the toxin. In this work, we report the
three-dimensional structure of ExoU in complex with a
partner molecule, SpcU. ExoU contains three distinct
regions, and the fold suggests how ExoU binds to the
membrane or other molecules within the target cell and
becomes activated. In addition, we also show that once it
is translocated into the cell, ExoU co-localizes with
intracellular organelles of the endosomal pathway, poten-
tially in an attempt of the target cell to destroy the toxin.
This work provides new insight into the cellular destruc-
tion mechanism of this aggressive toxin and could be a
basis for the development of new inhibitors of P.
aeruginosa pathogenesis.
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PLoS Pathogens | www.plospathogens.org 2 April 2012 | Volume 8 | Issue 4 | e1002637Figure 1. The crystal structure of ExoU in complex with its chaperone SpcU. (A) Schematic diagram of the ExoU construct used in this work
and limitations of different domains. The first and last ExoU residues observed in the electron density map are Gly53 and Glu685. The catalytic domain
is inserted within the first and second bridging subdomains. (B) ExoU folds into three distinct domains and its N-terminal b-strand is paired with
SpcU’s b-sheet. The bridging domain (yellow) contains elements that are both N-terminal and C-terminal to the catalytic domain (blue). The
membrane-binding domain makes few contacts with the other domains of ExoU. (C) SpcU (green) is a type IA T3SS chaperone. The N-terminus of
ExoU, packs as a b-strand against the central 5-stranded SpcU sheet. For clarity, only the asymmetric unit is shown.
doi:10.1371/journal.ppat.1002637.g001
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is followed by the all-helical C-terminal subdomain (residues 480–
580). The bridging domain itself has no significant structural
similarity with any known folds, as determined by the DALI server
(http://ekhidna.biocenter.helsinki.fi/dali_server/). Due to its in-
tercalated position between catalytic and membrane-binding
domains, it is possible that its function is uniquely to serve as a
‘platform’ to place both functionally critical domains in close
proximity.
Residues 106–471 delimit the catalytic, phospholipase domain,
which is composed of an a/b hydrolase fold with a 6-stranded
central b-sheet surrounded by 10 a-helices (Figures 1 and 2a). The
sheet displays a superhelical twist with b strands 8 and 10 lying at
approximately 90u to each other. The catalytic serine (Ser142) is
located at an elbow between b6 and the following helix, in a
funnel-like region surrounded by a number of flexible loops. A
triple glycine sequence (Gly111, 112, 113), in close proximity,
provides its backbone atoms as an oxyanion hole that potentially
stabilizes the charge of the transition state intermediate in the
phospholipase reaction (Figure 2a). This structural arrangement is
highly similar to that of a well-studied and potent phospholipase,
human cPLA2, whose structure also carries a twisted b-sheet that
prominently displays the catalytic serine in proximity to the
oxyanion hole [51] (Figure 2b). Additionally, the structure of
cPLA2 harbors an active site ‘cap’ – a presumably flexible region
that must be displaced in order to enable substrate access into the
active site. It is precisely in this ‘cap’ region that is located the
catalytic aspartate residue, essential for phospholipase activity
[51]. In the structure of ExoU, this region is also found to be
flexible, and the catalytic aspartate (Asp344) is not traceable in the
electron density map (Figure 2a), suggesting not only that ExoU
could also harbor a ‘cap’ region, but that the structure presented
here is in the ‘open ’, and potentially inactive, conformation.
Interestingly, Lys178, shown to be the target for ubiquitination
once ExoU upon membrane localization, is located within the
phospholipase domain, in close proximity to the active site
(Figures 3a, 3b). Its side chain is located approximately 7 A ˚ away
from the active site serine, in a region that displays high flexibility.
This strategic localization could favor the ability of this particular
lysine residue to become ubiquitinated (see below).
The C-terminus of ExoU has been shown to play a key role in
membrane targeting, and numerous modifications of this region
that have an impact ExoU’s cytotoxicity have been described,
including the deletion of residues 679–683, which results in P.
aeruginosa strains whose cytotoxicity potential is greatly diminished
[31,37–40,50]. Our structure reveals that the C-terminus of ExoU
forms a distinct domain (encompassing residues 588–687) that
folds into a 4-helical bundle (red in Figures 1 and 3a). One group
of residues whose mutation affects ExoU intracellular functionality
(Ile609, Ile654, Leu651, Ala678; [38,40]) makes hydrophobic
interactions within the bundle itself, and their mutation into polar
residues could destabilize the non-polar character of the interior of
the bundle. A second group (Arg661, Lys679, Arg682, Asn683
[38,39]) is exposed on the surface of ExoU, with Arg661 located
on a loop that precedes the C-terminal a-helix that harbors amino
acids 679–683 (Figures 3a and 3b). Interestingly, residues 679,
682, and 683 form a polar, mostly basic ‘backbone’ that could
bind to negatively charged eukaryotic phospholipids (Figure S3),
and facilitate lipid bilayer recognition. To explore this idea, we
performed protein-lipid overlay assays and demonstrated that
ExoU strongly interacts with PI(4,5)P2 (Figure 3c), a negatively-
charged polyvalent phospholipid that is abundant in the cytosolic
leaflet of the PM. The non-catalytic mutant ExoU-S142A also
displays a strong affinity for PI(4,5)P2, but this interaction is
completely abolished in the case of a mutant lacking residues 679–
683 (Figure 3c), which suggests a direct role of PI(4,5)P2
interaction for ExoU PM localization. Our results thus provide a
molecular explanation for ExoU’s PM targeting, which constitutes
the toxin’s premier localization upon T3SS translocation.
Ubiquitinated ExoU is targeted to endosomes
Upon localization to the PM, ExoU becomes ubiquitinated on
Lys178, a modification which has a small effect on its intracellular
turnover rate [39]. In order to explore the fate of translocated
ExoU, we adapted the Ubiquitin-mediated Fluorescence Com-
plementation (UbFC) method [52] to directly visualize ubiquiti-
nated ExoU (Ub-ExoU) in eukaryotic cells. Catalytically-inactive
ExoU-S142A was fused to the C-terminal fragment of the Venus
fluorescent protein (generating ExoU-S142A-VC), and Ub to its
complementary N-terminal fragment (generating VN-Ub;
Figure 4a). Co-transfection of the two plasmids, but not single
transfections, led to a fluorescent signal located at the cell
periphery, but also revealed punctate structures throughout the
cytoplasm (Figure 4b upper panel). To ascertain that the observed
signal was specific, we tested the fluorescence complementation
potential of a mutated, non-conjugatable Ub protein, in which the
7 endogenous lysine residues and the two C-terminal glycine
residues were modified (VN-Ub Mut). No fluorescence comple-
Figure 2. The catalytic domain of ExoU displays an a/b hydrolase fold. (A) Ser142 is in close proximity to the Gly111–113 elbow, which acts
as an oxyanion hole for the phospholipase-catalyzed reaction. The second member of the Ser-Asp catalytic dyad, Asp344, is located in a flexible
region that is not traceable in the electron density map. The overall arrangement of the core region of ExoU’s catalytic domain is reminiscent of that
of human cPLA2 (B), which also harbors the catalytic aspartate in a moveable ‘cap’ (in violet).
doi:10.1371/journal.ppat.1002637.g002
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and VN-Ub Mut, whereas both proteins were successfully
expressed as evidenced by immunofluorescence detection of
tagged proteins (Figure 4b, bottom panels). These observations
suggested that the punctate pattern observed by Phillips et al upon
transfection of GFP-ExoU-S142A into eukaryotic cells [32] could
reflect targeting of the ubiquitinated form of ExoU to specific
intracellular compartments.
In order to identify this intracellular location, we compared the
fluorescence complementation signal with the localization of
proteins of known distribution. Ub-ExoU-S142A did not co-
localize with endoplasmic reticulum nor with Golgi markers
(Figure S4), but was targeted to acidic organelles, as evidenced by
its co-localization with the early endosome marker EEA1 and with
lysotracker-stained compartments (Figure 5a, top panels). Since
ubiquitination of ExoU has been proposed to involve Lys63-linked
Ub chains [39], we tested a Venus-fusion of a Ub mutant in which
all Lys residues, except Lys63, were mutated to Arg (VN-Ub-K63).
ExoU-S142A-Ub K63 co-localized with lysotracker (Figure 5a,
bottom panel), confirming that K63-linked chains of Ub are most
likely responsible for ExoU targeting to endosomal compartments.
In order to study ExoU targeting in the natural context of
infection, we engineered a P. aeruginosa strain that translocates
catalytically inactive ExoU-S142A upon induction of the T3SS
into HeLa cells (PaDST+ExoU). Confocal microscopy analyses of
infected cells revealed the presence of ExoU at the PM, as
previously identified [32,37,39], but also revealed that translocated
ExoU co-localizes with EEA1 (Figure 5b top panel and Video S1).
In order to relate this localization to the ubiquitination of ExoU,
we generated a P. aeruginosa strain that expresses ExoU-S142A-
Figure 3. Membrane-binding, ubiquitination, and catalysis are structurally intertwined. (A) Mutations in the C-terminus of ExoU
[31,32,37–40] that abrogate membrane binding and cytotoxicity are all located within the four-helical bundle (red). This region is located on the same
face of the molecule as the catalytic region, as well as Lys178 (left). (B) Residues 679–683 are exposed to solvent, in a potential appropriate orientation
for bilayer recognition. (C) Protein-lipid overlays of wt ExoU, ExoU-S142A and ExoU-D679–683 reveal that the C-terminal region is essential for a
strong, specific interaction with PI(4,5)P2. TG, triglyceride; DAG, diacylglycerol; PA, phosphatidic acid; PS, phosphatidylserine; PE, phosphatidyleth-
anolamine; PC, phosphatidylcholine; PG, phosphatidylglycerol; CL, cardiolipin; PI, phosphatidyl-inositol; PI(4)P, phosphatidylinositol 4 phosphate;
PI(4,5)P2, phosphatidylinositol (4,5) di-phosphate; PI(3,4,5)P3, phosphatidylinositol (3,4,5) triphosphate; chol, cholesterol; SM, sphingomyelin; SGC, 3
sulfogalactosylceramide. Blank=no lipid spotted.
doi:10.1371/journal.ppat.1002637.g003
Figure 4. Direct visualization of Ub-ExoU by UbFC. (A) Schematic representation of the plasmid constructs used for UbFC. The genes from
which the different fragments were amplified are indicated within the boxes, and the number of residues of each fragment is indicated in
parentheses. (B) ExoU-S142A-VC and VN-Ub (upper panel) or ExoU-S142A-VC and VN-Ub Mut (lower panels) were co-expressed in HeLa cells, and
fluorescence complementation was observed 36 h after transfection. Immunodetection of fusion proteins with the anti-HA and the anti-FLAG
antibodies was performed to confirm protein expression Bars, 12 mm. Pearson’s correlation coefficient for Fig. 4B top=0.727.
doi:10.1371/journal.ppat.1002637.g004
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analyses of HeLa cells infected with this strain did not indicate any
co-localization of this mutant with endosomal compartments, but
a prominent PM staining. These observations thus indicate that
ExoU’s co-localization with endosomes is directly dependent on its
ubiquitination of Lys178.
Stirling et al. showed that residues 679–683, located at the
extremity of the C-terminal helical bundle (Figure 3b) are required
for ubiquitination [39]. The intracellular fate of this mutant was
investigated by constructing a P. aeruginosa strain that expresses
ExoU-S142A-D679–683. Confocal microscopy images of infected
HeLa cells indicated that this mutant form of ExoU not only failed
to associate with the PM, but was also not able to co-localize with
EEA1 (Figure 5b, bottom right panel). These observations point
clearly to the interdependence of the membrane-binding bundle,
of Lys178 ubiquitination, and of phospholipase activity in
mediating the cellular functionality of ExoU.
Discussion
The acute cytotoxic potential of ExoU-carrying P. aeruginosa
strains is evidenced by the significant damage suffered by a variety
of cell lineages and the toxin’s ability to rapidly destroy lung tissue
in vivo [24,25]. The structural and functional characterization of
this unique T3SS toxin, reported here, indicates how this multi-
domain molecule can intertwine functionalities, and sheds light on
its intracellular fate upon translocation.
In the bacterial cytosol and prior to translocation, ExoU is
bound to SpcU [23], a small, acidic Type IA T3SS chaperone.
Type IA chaperones are typically dimeric, and contact their
cognate effectors mostly through the latter’s N-terminus, which is
‘wrapped around’ the chaperone dimer [3,45–48,53]. Here, we
identify the two key recognition sites between SpcU and ExoU as
the b motif and a hydrophobic cavity at the center of the
chaperone, both of which have been described for other Type IA
chaperone:effector complexes, such as InvB:SipA from Salmonella
[46], SycE:YopE (23–78) from Yersinia [47], and SicP:SptP (35–
139) from Salmonella [48]. In all of these structures, the chaperone-
binding domain (CBD) is localized within the effector’s N-terminal
region. SpcU maintains the N-terminal residues of ExoU in a non-
globular conformation (albeit still maintaining the structure of b1).
This could allow ExoU to be ready for secretion and rapid
unfolding upon recognition by the base of the T3SS, as suggested
for other systems [5,54]. This hypothesis is also supported by
mutagenesis studies performed on the b motifs of SicP:SptP and
SycE:YopE, which reveal that modification of a few strategic
residues suffices for total disruption of chaperone:effector interac-
tions [46].
Figure 5. Ub-ExoU is targeted to endosomes. (A) Co-localization of Ub-ExoU with endosomal markers. ExoU S142A-VC was co-transfected with
VN-Ub (upper panel) or with VN-Ub K63 (bottom panel). 36 h later, cells were stained with the anti-EEA1, or treated with lysotracker red. Pearson’s
correlation coefficients correspond to 0.692, 0.570, and 0.801 the top left, top right, and bottom panels, respectively. (B). HeLa cells were infected for
3 h with PaDST+ExoU S142A (upper panel), PaDST+ExoU S142A-K178R or PaDST+ExoU S142A D679–683 (bottom panel), fixed and immunolabeled
with anti-ExoU and anti-EEA1 antibodies. Single two-channel confocal images are presented. The Pearson’s correlation coefficient for EEA1-
ExoU=0.213. Bars, 12 mm.
doi:10.1371/journal.ppat.1002637.g005
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the catalytic Ser142 is not exposed on the surface of the molecule,
but is located within a cleft surrounded by flexible regions. This
suggests that the active site does not have unobstructed access to its
phospholipidic substrates. Local conformational changes could
thus be required to occur upon membrane targeting, leading to
active site exposure, which could constitute a potential mechanism
of protection of membranes (bacterial or host) that are not
originally intended for targeting. Notably, the localization of a
phospholipase active site serine residue within a funnel-like region
protected by a flexible lid carrying the catalytic aspartate has been
observed in the structure of the eukaryotic enzyme cPLA2 [51],
which undergoes interfacial activation upon binding to a
membranous interface [55,56]. In cPLA2, closure of the lid region
is necessary not only for formation of a ‘complete’ active site, but
also for masking of a large hydrophobic region that surrounds the
catalytic serine [51]. In ExoU, the localization of Asp344, the
second member of the catalytic dyad, in a flexible region in close
proximity to Ser142, provides additional supportive evidence for
the requirement for local conformational changes in the vicinity of
Ser142 in order to place Asp344 in position for catalysis. This
suggests that the structure presented here is in an ‘open’, inactive
conformation, and local conformational changes are required to
‘close’ the flexible loops and define the placement of Asp344.
How could such conformational modifications be initiated? The
data presented here, including our structural analysis and
phospholipid binding studies, together with mutagenesis results,
spectroscopic studies, and cofactor identification experiments
performed by other laboratories [31–33,37,38,40–44] provide a
working hypothesis. ExoU binds specifically to PI(4,5)P2, the
major phosphoinositide of the eukaryotic plasma membrane, and
the C-terminal a-helical bundle plays a key role in this association
(Figure 3c). Notably, this C-terminal region is of central
importance for ExoU’s phospholipase activity [31,38–40], an
observation that reveals the functional interdependence of
membrane-binding and catalytic domains. Thus, upon transloca-
tion of ExoU into target cells and PM recognition by the C-
terminal domain, ExoU could undergo a conformational change
that allows partial insertion of the nearby catalytic domain, and
thus the active site, into the bilayer. The proximity of the substrate,
and the interaction with a eukaryotic cofactor, could suffice to
locally modify the flexible regions that surround the active site
region, allowing the catalytic serine to have access to phospholip-
ids. The distance between the C-terminus of ExoU and the active
site is of approximately 25 A ˚, and the lack of many contact points
between these two domains suggests that some level of rotation
could occur between them in order to place the active site in an
optimal position. This suggestion is also in agreement with recent,
elegant studies by Benson et al., who used spin-labeling electron
paramagnetic resonance spectroscopy to identify conformational
changes in the C-terminus domain and within the active site of
ExoU, in the presence of both liposomes and of a potential
eukaryotic cofactor [43]. Strikingly, Benson et al. also identified
that in the absence of cofactor or lipids, ExoU displays multiple
conformations, which is in particular agreement with the
considerable flexibility observed in the region of the active site
in our apo structure. In another recent study, ubiquitin and
ubiquitinated proteins were also identified as cofactors, and
potential activating agents, for ExoU [44]. Considering that many
ubiquitination processes occur in the vicinity of the PM, these
observations are also in agreement with the model discussed
above.
ExoU has been reported to be ubiquitinated by the host
machinery on its Lys178 upon translocation and binding to the
PM [39]. Our structure reveals that Lys178 is located within the
catalytic domain, on the same side of the molecule as both the
active site and the membrane-binding domain (Figures 3a and 3b).
Following the model described above, the partial imbedding of the
catalytic domain of ExoU into the bilayer (upon recognition of the
PM through the C-terminal region and binding to cofactor(s))
would place Lys178 in close proximity to ubiquitin ligase
complexes located in the vicinity [57], allowing for rapid
ubiquitination. Notably, we show that ubiquitinated ExoU is
observed at the level of the organelles of the endo-lysosomal
pathway, both by transfection studies using fluorescence comple-
mentation, and confocal microscopy analyses of P. aeruginosa-
infected eukaryotic cells. It has been previously shown that a P.
aeruginosa strain carrying the non-ubiquitinated variant ExoU-
K178R is as cytotoxic to eukaryotic cells as the wild type strain
[39], suggesting that endosomal localization is not linked to
ExoU’s cytotoxic potential. Rather, the effects described here
could represent an attempt by the eukaryotic cell to protect itself
from ExoU’s phospholipase action by targeting it to lysosomes,
viewing its potential destruction. Given the rapid effect of ExoU
on target cells, however, this protection mechanism does not seem
to be efficient enough to offer protection from the toxin’s ability to
efficiently disrupt membranes, which is at the basis for the
extremely aggressive nature of ExoU-expressing P. aeruginosa
strains.
In summary, the structure of ExoU presented here reveals the
toxin in its chaperone-bound, inactive, pre-secretion conforma-
tion. Since ExoU has broad substrate specificity, this conformation
most likely prevents the toxin from binding to bacterial
membranes, enabling the bacterium to be protected from ExoU’s
phospholipase action. Thus, our structural data provide a basis for
the study of conformational changes that must accompany ExoU’s
activation upon binding to cellular factors, which in turn lead to
phospholipase activity and cytotoxicity. Finally, the structure of
the ExoU:SpcU complex could serve as a basis for the
development of ligands designed to stabilize this conformation,
which in turn could prevent ExoU’s secretion and thus diminish
bacterial pathogenicity.
Methods and Materials
Protein expression, crystallization, and structure solution
ExoU (1–687) and SpcU (1–137) were first amplified from a
clinical P. aeruginosa strain (GESPA 1999 collection). Both full-
length forms of ExoU and SpcU were initially cloned into
pETDueT-1, co-expressed in E. coli BL21/DE3, and expression
was performed with 1 mM isopropyl 1-thio-b-D-thiogalactopyr-
anoside for 3 h at 37uC. The complex was purified by nickel
affinity chromatography (Ni-NTA, Qiagen) and gel filtration (HR
10/60 column, GE Healthcare) techniques. This strategy yielded
thin crystals that diffracted poorly. Limited proteolysis experiments
with thrombin identified that removal of the first 29 residues of
ExoU and the last 10 residues of SpcU generated better quality
crystals. Thus a thrombin site was introduced between residues 29
and 30 of ExoU, and a stop codon after residue 127 of SpcU, in
the same pETDueT vector. The complex was expressed as
described above. After Ni affinity chromatography and treatment
with thrombin, ExoU:SpcU was further purified a MonoQ
column (GE Healthcare) in 50 mM Tris-HCl pH 8.8, 1 mM
EDTA (elution gradient, 0–1 M NaCl). Samples for crystallization
were gel filtered in 25 mM Tris-HCl pH 8.0, 100 mM NaCl,
1 mM EDTA. Crystals of the ExoU (29–687):SpcU (1–127)
complex were obtained in 0.1 M KNO3, 20% PEG 3350. A SAD
data set on the selenium edge was collected at the European
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France) to a resolution of 2.94 A ˚. Data collection and refinement
statistics are included in Table S1.
Diffraction images were indexed and scaled with XDS [58].
Initial selenomethionine sites were identified with PHENIX
AutoSol [59]. Initial experimental density maps were improved
after model building and phase extension using PHENIX.
PARROT [60] and PIRATE [61]were used in density modifica-
tion-phase improvement steps interspersed with cycles of auto-
matic model-building using BUCCANEER [62]. The ExoU:SpcU
structure was completed by cycles of manual model-building using
COOT 0.6.2 [63]. Water molecules were added to the residual
electron density map using ARP/wARP 7.1.1 [64]. Cycles of
restrained refinement were performed with REFMAC 5.6 [65] as
implemented in the CCP4 program suite (Table S1). Stereochem-
ical verification was performed by PROCHECK [66] and
secondary structure assignment by DSSP [67]. Figures were
generated with PyMol (www.pymol.org).
Mass spectrometry
Native mass spectrometry measurements of ExoU:SpcU were
carried out with a Micro-TOF-Q Bruker mass spectrometer
(Wissembourg, France) with an electrospray ion source. Mass
spectra were recorded in the 500–7000 mass-to-charge (m/z)
range. Sample concentration was 15 mm in 20 mm ammonium
acetate and continuously infused at a flow rate of 7 ml/min. Data
were acquired in the positive mode and calibration was performed
using a solution of 0.1 mg/ml CsI in water/isopropyl alcohol (1:1,
v/v). The system was controlled with the MicrOTOF Control
software package and data were processed with DataAnalysis.
Construction of plasmids for transfection of HeLa cells
Plasmids encoding ExoU S142A-VC and VN-Ub originate
from Addgene plasmids 22011 and 22010, initially provided by
Dr. C.-D. Hu, Purdue Univ. ExoU was cloned N-terminally to the
VC155 fragment, whereas Ub was cloned C-terminally to the
VN173 fragment. The S142A mutation was inserted into the
ExoU sequence via site-directed mutagenesis (Stratagene). To limit
background fluorescence [68], we deleted specific regions of the
Venus fragments to generate VN158-Ub and ExoU-S142A-
VC159, and introduced the V150L mutation in the VN fragment,
to obtain plasmids ExoU-S142A-VC and VN-Ub as described in
[69]. We amplified Ub K63 from Addgene plasmid 17606
(donated by Dr T. Dawson), and cloned it in our modified
pBiFC-VN plasmid. Insertion of the Lys63Arg, Gly75Lys and
Gly76Leu substitutions led to the control plasmid VN-Ub Mut.
Construction of mutant ExoU-expressing P. aeruginosa
strains
A 3-kb-long DNA fragment containing the promoter and the
sequence of the exoUspcU operon from the strain of the GESPA
collection [70] was cloned into the replicative pUCP20 plasmid.
The S124A and K178R mutations, as well as the 679–683 deletion
were introduced into the exou sequence using Quick Change
Mutagenesis kit (Stratagene). The different plasmids were
transferred by transformation [71] into the P. aeruginosa CHADS-
Tlox strain kindly provided by Prof B. Polack.
Antibodies and probes
Antibodies used for immunofluorescence co-staining include an
anti-HA from Covance (AFC-101P), an anti-FLAG from Euro-
medex (EL1B11), an anti-EEA1 from BD transduction (610457)
and an anti-GORASP2 from Euromedex (10598-1-AP). The anti-
ExoU antibodies were raised against His6-ExoU in rabbits by
Eurogentec, as described by the manufacturer. Specific anti-ExoU
antibodies were immunopurified. Lysotracker Red (Molecular
probes) was added at 500 nM and incubated for 1 h at 37uC
before fixation.
Mammalian cell transfections and immunofluorescence
microscopy
One day before transfection, Hela cells were seeded on 12-mm
coverslips. Transient transfections were performed using Jet-
prime (Polyplus transfection), following the manufacturer’s
instructions. For bifluorescence complementation assays, both
plasmids were added in equal quantities. On the following day,
cells were fixed with 2% paraformaldehyde and permeabilized
with 0.2% TX-100. Primary antibodies were added for 30 min
at 37uC, washed away and the Alexa-fluor 594 conjugated anti-
mouse antibody (Molecular Probes) was incubated for 1 h at
room temperature. Nuclei were counterstained with DAPI.
Images were collected with an inverted Olympus IX81
epifluorescence motorized microscope equipped with a motor-
ized piezo stage (Ludl Electronic Products, USA) and a Retiga-
SRV CCD camera (QImaging) driven by VOLOCITY software
( I m p r o v i s i o n )w i t hab i n n i n go f1 ,u s i n gaP l a n A p o6 0 6NA1.42
objective (Olympus). Images were deconvoluted using the
Volocity 5.5 software.
P. aeruginosa infection and analysis by confocal
microscopy
Sparse HeLa cells were infected with bacteria in exponential
growth at an MOI value of 10 and incubated for 3 h at 37uCi n
RPMI. At this point, approximately 10% of the total amount of
ExoU is ubiquitinated. Subsequently, cells were washed and fixed
in 4% paraformaldehyde and 0.5% Triton X-100 and labeled with
anti-ExoU and anti-EEA1 antibodies. After incubation with
secondary fluorescent antibodies, cells were observed with a
confocal fluorescent microscope (Leica TCS SP2). Images were
treated with the ImageJ software for 3D reconstruction.
Detection of protein-lipid interactions
Membrane lipid strips (Echelon Biosciences) were blocked in
PBS+4% milk, and incubated overnight with proteins at 0.5 mg/
mL. Detection of bound proteins was performed as recommended
by the manufacturer.
Supporting Information
Figure S1 Association between ExoU and its chaperone
SpcU. (A) SpcU has a type IA T3SS chaperone fold whose central
b-sheet is completed by one b-strand from the effector molecule,
ExoU, forming a 6-stranded structure. The SpcU ‘tunnel’ that
harbors the ExoU’s b1 strand is highly hydrophobic, as seen in the
electrostatic surface representation in (B), where basic residues are
shown in blue and acidic in red. An additional, minor interaction
region involves the membrane binding domain, in which the
backbone carboxyl group of SpcU’s Val49 and the side chain
carbonyl group of Ser51 make hydrogen bonds with the NH2
group of Arg633 and the ND2 moiety of Asn657, respectively. (C)
A symmetry mate within the C2 cell reveals the formation of a
SpcU dimer that is wrapped by the N-terminus of ExoU.
(TIF)
Figure S2 The bridging domain of ExoU is subdivided
into two subdomains. The N-terminal subdomain harbors a 4-
stranded region formed by strands that correspond to sequences
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subdomain, fully helical, is composed of residues 481–580.
(TIF)
Figure S3 Electrostatic surface diagram of ExoU, with a
direct view to the C-terminus domain. Residues 679–683
are not only completely solvent exposed but also generate a polar/
basic ‘backbone’ that could recognize the phospholipid bilayer.
(TIF)
Figure S4 Ub-ExoU is not targeted to the Golgi. 36 h after
co-transfection of ExoU-VC and VN-Ub, cells were stained with
an anti-GORASP2 antibody to label the cis-Golgi. The Person’s
correlation coefficient corresponds to 0.0546. Bars, 12 mm.
(TIF)
Table S1 Data collection and structure refinement
statistics.
(TIF)
Video S1 Co-localization of ExoU and EEA1 in a stack of
Z-sections of infected HeLa cells. Images were acquired on a
confocal microscope for ExoU (red) and EEA1 (green) immuno-
fluorescence and collected in 22 Z-sections. Co-localization in
early endosomes appears in yellow.
(AVI)
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